Clinical Trials Details

NRG-GI004 COMMIT (Colon)

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

Objective

Key eligibility: Without previous chemotherapy for metastatic disease, dMMR by IHC or NGS

» Learn more about this trial

Clinical Trial Categories

• Cancers and Other Neoplasms